Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash from Investing Activities (2020 - 2022)

Historic Cash from Investing Activities for Guided Therapeutics (GTHP) over the last 8 years, with Q4 2022 value amounting to -$3000.0.

  • Guided Therapeutics' Cash from Investing Activities rose 2500.0% to -$3000.0 in Q4 2022 from the same period last year, while for Mar 2023 it was -$21000.0, marking a year-over-year increase of 2222.22%. This contributed to the annual value of -$31000.0 for FY2022, which is 12142.86% down from last year.
  • Guided Therapeutics' Cash from Investing Activities amounted to -$3000.0 in Q4 2022, which was up 2500.0% from -$14000.0 recorded in Q1 2022.
  • Guided Therapeutics' Cash from Investing Activities' 5-year high stood at -$1000.0 during Q3 2020, with a 5-year trough of -$14000.0 in Q1 2022.
  • Over the past 3 years, Guided Therapeutics' median Cash from Investing Activities value was -$4000.0 (recorded in 2021), while the average stood at -$4571.4.
  • Data for Guided Therapeutics' Cash from Investing Activities shows a peak YoY increase of 2500.0% (in 2022) and a maximum YoY decrease of 130000.0% (in 2022) over the last 5 years.
  • Quarter analysis of 3 years shows Guided Therapeutics' Cash from Investing Activities stood at -$1000.0 in 2020, then crashed by 300.0% to -$4000.0 in 2021, then increased by 25.0% to -$3000.0 in 2022.
  • Its Cash from Investing Activities was -$3000.0 in Q4 2022, compared to -$14000.0 in Q1 2022 and -$4000.0 in Q4 2021.